- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Oric Pharmaceuticals Stock Rises 6.5%, Analysts Maintain Buy Ratings
Shares of the biotech company climb despite broader market decline
Apr. 9, 2026 at 4:36pm
Got story updates? Submit your updates here. ›
Oric Pharmaceuticals' stock rise reflects investor confidence in the company's ability to develop innovative cancer therapies that can overcome drug resistance.South San Francisco TodayOric Pharmaceuticals (NASDAQ:ORIC) saw its stock price rise 6.5% on Thursday, trading as high as $9.50 per share. The company, which is focused on developing cancer therapies to overcome drug resistance, saw trading volume decline 78% from its average daily levels. Analysts have maintained their buy ratings on the stock, with price targets ranging from $15 to $25.
Why it matters
Oric Pharmaceuticals' stock performance is noteworthy given the broader market decline, indicating potential investor confidence in the company's pipeline and ability to navigate the competitive oncology landscape. The stock's rise also suggests analysts remain bullish on the company's prospects, despite the challenges facing the biotech industry.
The details
Oric Pharmaceuticals' lead candidate, ORIC-101, is currently in Phase 1/2 trials for patients with solid tumors who have acquired resistance to standard therapies. The company's focus on overcoming drug resistance in cancer treatment is seen as a key differentiator and potential growth driver. Analysts have cited the company's strong cash position and experienced management team as additional factors supporting their positive outlook.
- Oric Pharmaceuticals' stock rose 6.5% on Thursday, April 9, 2026.
- The company's shares traded as high as $9.50 during the session.
The players
Oric Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company focused on developing cancer therapies to overcome drug resistance.
ORIC-101
Oric Pharmaceuticals' lead candidate, a selective, orally available antagonist of the glucocorticoid receptor currently in Phase 1/2 trials for patients with solid tumors who have acquired resistance to standard therapies.
What they’re saying
“We remain bullish on Oric Pharmaceuticals' prospects, given the strength of its pipeline and experienced management team.”
— Oppenheimer Analyst, Research Analyst
“Oric Pharmaceuticals' focus on overcoming drug resistance in cancer treatment is a key differentiator and potential growth driver for the company.”
— HC Wainwright Analyst, Research Analyst
What’s next
Investors will be closely watching Oric Pharmaceuticals' progress with its lead candidate ORIC-101 as the company continues its Phase 1/2 trials. Any updates on the drug's development and potential regulatory milestones will be closely followed by the market.
The takeaway
Oric Pharmaceuticals' stock performance and analyst support highlight the potential of its approach to addressing drug resistance in cancer treatment. As the company continues to advance its pipeline, its ability to navigate the competitive oncology landscape and deliver innovative therapies will be key to its long-term success.
